Viewing Study NCT02282020


Ignite Creation Date: 2025-12-25 @ 4:08 AM
Ignite Modification Date: 2026-02-25 @ 7:08 PM
Study NCT ID: NCT02282020
Status: COMPLETED
Last Update Posted: 2022-07-26
First Post: 2014-10-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BRCA, ovarian, platinum, chemotherapy, View